serw-MX  [xml]  
 


    
 DeCS Categories

C04 Neoplasms .
D05 Macromolecular Substances .
D05.750 Polymers .
D05.750.741 Polyethylene Glycols .
D05.750.741.125 Certolizumab Pegol .
D12 Amino Acids, Peptides, and Proteins .
D12.644 Peptides .
D12.644.276 Intercellular Signaling Peptides and Proteins .
D12.644.276.374 Cytokines .
D12.644.276.374.480 Lymphokines .
D12.644.276.374.480.438 Lymphotoxin-alpha .
D12.644.276.374.500 Monokines .
D12.644.276.374.500.800 Tumor Necrosis Factor-alpha .
D12.644.276.374.750 Tumor Necrosis Factors .
D12.644.276.374.750.500 Lymphotoxin-alpha .
D12.644.276.374.750.626 Tumor Necrosis Factor-alpha .
D12.644.541 Peptide Fragments .
D12.644.541.500 Immunoglobulin Fragments .
D12.644.541.500.650 Immunoglobulin Fab Fragments .
D12.644.541.500.650.250 Certolizumab Pegol .
D12.776 Proteins .
D12.776.124 Blood Proteins .
D12.776.124.486 Immunoproteins .
D12.776.124.486.485 Immunoglobulins .
D12.776.124.486.485.114 Antibodies .
D12.776.124.486.485.114.224 Antibodies, Monoclonal .
D12.776.124.486.485.114.224.060 Antibodies, Monoclonal, Humanized .
D12.776.124.486.485.114.224.060.500 Certolizumab Pegol .
D12.776.124.486.485.114.619 Immunoglobulin Isotypes .
D12.776.124.486.485.114.619.393 Immunoglobulin G .
D12.776.124.486.485.114.619.393.261 Etanercept .
D12.776.124.486.485.680 Immunoglobulin Fragments .
D12.776.124.486.485.680.650 Immunoglobulin Fab Fragments .
D12.776.124.486.485.680.650.250 Certolizumab Pegol .
D12.776.124.790 Serum Globulins .
D12.776.124.790.651 Immunoglobulins .
D12.776.124.790.651.114 Antibodies .
D12.776.124.790.651.114.224 Antibodies, Monoclonal .
D12.776.124.790.651.114.224.060 Antibodies, Monoclonal, Humanized .
D12.776.124.790.651.114.224.060.500 Certolizumab Pegol .
D12.776.124.790.651.114.619 Immunoglobulin Isotypes .
D12.776.124.790.651.114.619.393 Immunoglobulin G .
D12.776.124.790.651.114.619.393.261 Etanercept .
D12.776.124.790.651.680 Immunoglobulin Fragments .
D12.776.124.790.651.680.650 Immunoglobulin Fab Fragments .
D12.776.124.790.651.680.650.250 Certolizumab Pegol .
D12.776.124.900 Tumor Necrosis Factor-alpha .
D12.776.377 Globulins .
D12.776.377.715 Serum Globulins .
D12.776.377.715.548 Immunoglobulins .
D12.776.377.715.548.114 Antibodies .
D12.776.377.715.548.114.224 Antibodies, Monoclonal .
D12.776.377.715.548.114.224.200 Antibodies, Monoclonal, Humanized .
D12.776.377.715.548.114.224.200.500 Certolizumab Pegol .
D12.776.377.715.548.114.619 Immunoglobulin Isotypes .
D12.776.377.715.548.114.619.393 Immunoglobulin G .
D12.776.377.715.548.114.619.393.261 Etanercept .
D12.776.377.715.548.680 Immunoglobulin Fragments .
D12.776.377.715.548.680.650 Immunoglobulin Fab Fragments .
D12.776.377.715.548.680.650.250 Certolizumab Pegol .
D12.776.395 Glycoproteins .
D12.776.395.560 Mucoproteins .
D12.776.395.560.631 Mucins .
D12.776.395.560.631.050 CA-125 Antigen .
D12.776.395.930 Tumor Necrosis Factor-alpha .
D12.776.467 Intercellular Signaling Peptides and Proteins .
D12.776.467.374 Cytokines .
D12.776.467.374.480 Lymphokines .
D12.776.467.374.480.438 Lymphotoxin-alpha .
D12.776.467.374.500 Monokines .
D12.776.467.374.500.800 Tumor Necrosis Factor-alpha .
D12.776.467.374.750 Tumor Necrosis Factors .
D12.776.467.374.750.500 Lymphotoxin-alpha .
D12.776.467.374.750.626 Tumor Necrosis Factor-alpha .
D12.776.543 Membrane Proteins .
D12.776.543.750 Receptors, Cell Surface .
D12.776.543.750.690 Receptors, Death Domain .
D12.776.543.750.690.750 Receptors, Tumor Necrosis Factor, Type I .
D12.776.543.750.705 Receptors, Immunologic .
D12.776.543.750.705.852 Receptors, Cytokine .
D12.776.543.750.705.852.760 Receptors, Tumor Necrosis Factor .
D12.776.543.750.705.852.760.232 Etanercept .
D12.776.543.750.705.852.760.597 Receptors, Tumor Necrosis Factor, Type I .
D23 Biological Factors .
D23.050 Antigens .
D23.050.285 Antigens, Neoplasm .
D23.050.285.050 Antigens, Tumor-Associated, Carbohydrate .
D23.050.285.050.225 CA-125 Antigen .
D23.050.550 Epitopes .
D23.050.550.325 Antigens, Tumor-Associated, Carbohydrate .
D23.050.550.325.225 CA-125 Antigen .
D23.101 Biomarkers .
D23.101.140 Biomarkers, Tumor .
D23.101.140.075 Antigens, Tumor-Associated, Carbohydrate .
D23.101.140.075.225 CA-125 Antigen .
D23.529 Intercellular Signaling Peptides and Proteins .
D23.529.374 Cytokines .
D23.529.374.480 Lymphokines .
D23.529.374.480.438 Lymphotoxin-alpha .
D23.529.374.500 Monokines .
D23.529.374.500.800 Tumor Necrosis Factor-alpha .
D23.529.374.750 Tumor Necrosis Factors .
D23.529.374.750.500 Lymphotoxin-alpha .
D23.529.374.750.626 Tumor Necrosis Factor-alpha .
SP4 Environmental Health .
SP4.001 Health .
SP4.001.012 Environmental Illness .
SP4.001.012.098 Neoplasms .
SP4.046 Occupational Health .
SP4.046.452 Occupational Medicine .
SP4.046.452.698 Occupational Diseases .
SP4.046.452.698.879 Occupational Cancer .
SP4.046.452.698.879.165 Neoplasms .
 
 Terms
 Synonyms & Historicals
Documents
LILACS e MDL
 
Tumor Necrosis Factor-alpha .
Cachectin-Tumor Necrosis Factor .
TNF Superfamily, Member 2 .
TNFalpha .
Tumor Necrosis Factor .
Cachectin Tumor Necrosis Factor .
Tumor Necrosis Factor alpha .
Cachectin .
TNF-alpha .
Tumor Necrosis Factor Ligand Superfamily Member 2 .
Tumor Necrosis Factor .
Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. .
1.00
793111894
 
Certolizumab Pegol .
CDP 870 .
CDP870 .
Cimzia .
A polyethylene-glycolated Fab' fragment of TUMOR NECROSIS FACTOR antibody that binds specifically to TNF-ALPHA and neutralises it in a dose-dependent manner. It also inhibits the production of lipopolysaccharide-induced TNF-ALPHA and IL-1 BETA and is used to treat RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS. .
0.39
 
Etanercept .
Enbrel .
Recombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein .
TNF Receptor Type II-IgG Fusion Protein .
TNFR-Fc Fusion Protein .
TNR 001 .
TNR-001 .
TNT Receptor Fusion Protein .
TNTR-Fc .
001, TNR .
Fusion Protein, TNFR-Fc .
Protein, TNFR-Fc Fusion .
Recombinant Human Dimeric TNF Receptor Type II IgG Fusion Protein .
TNF Receptor Type II IgG Fusion Protein .
TNFR Fc Fusion Protein .
TNR001 .
A recombinant version of soluble human TNF receptor that binds specifically to TUMOR NECROSIS FACTOR and inhibits its binding with endogenous TNF receptors. It prevents the inflammatory effect of TNF and is used to treat RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS and ANKYLOSING SPONDYLITIS. .
0.34
 
Lymphotoxin-alpha .
Lymphotoxin .
Lymphotoxin-alpha3 .
Soluble Lymphotoxin-alpha .
alpha-Lymphotoxin .
Lymphotoxin alpha .
Lymphotoxin alpha3 .
Lymphotoxin-alpha, Soluble .
Soluble Lymphotoxin alpha .
Tumor Necrosis Factor beta .
alpha Lymphotoxin .
TNF Superfamily, Member 1 .
TNF-beta .
Tumor Necrosis Factor-beta .
Tumor Necrosis Factor Ligand Superfamily Member 1 .
A tumor necrosis factor family member that is released by activated LYMPHOCYTES. Soluble lymphotoxin is specific for TUMOR NECROSIS FACTOR RECEPTOR TYPE I; TUMOR NECROSIS FACTOR RECEPTOR TYPE II; and TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 14. Lymphotoxin-alpha can form a membrane-bound heterodimer with LYMPHOTOXIN-BETA that has specificity for the LYMPHOTOXIN BETA RECEPTOR. .
0.33
272872
 
Receptors, Tumor Necrosis Factor .
Receptors, Cachectin .
Receptors, TNF .
TNF Receptor .
Tumor Necrosis Factor Receptor .
Receptor, TNF .
Cachectin Receptors .
Tumor Necrosis Factor Receptors .
TNF Receptors .
TNFR 19189 .
Cell surface receptors that bind TUMOR NECROSIS FACTORS and trigger changes which influence the behavior of cells. .
0.33
4414490
 
CA-125 Antigen .
CA 125 Antigen .
Mucin-16 .
Antigen CA 125 .
Antigen, CA 125 .
Antigen, CA-125 .
Mucin 16 .
Antigen CA-125 .
A carbohydrate antigen that occurs in tumors of the ovary as well as in breast, kidney, and gastrointestinal tract tumors and normal tissue. While it is tumor-associated, it is not tumor-specific and may have a protective function against particles and infectious agents at mucosal surfaces. .
0.32
74207
 
Neoplasms .
Benign Neoplasms .
Malignancy .
Malignant Neoplasms .
Neoplasia .
Neoplasm .
Neoplasms, Benign .
Benign Neoplasm .
Cancers .
Malignancies .
Malignant Neoplasm .
Neoplasias .
Neoplasm, Benign .
Neoplasm, Malignant .
Neoplasms, Malignant .
Tumor .
Cancer .
Tumors .
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. .
0.32
6983285082
 
Receptors, Tumor Necrosis Factor, Type I .
CD 120a Antigen .
CD120a Antigen .
TNFR p60 .
TNFR-I .
TNFR1 .
TNFRSF1A (Tumor Necrosis Factor Receptor Superfamily, Member 1A) .
TNFRSF1A Receptor .
Tumor Necrosis Factor Receptor 1A .
Tumor Necrosis Factor Receptor Type 1 .
120a Antigen, CD .
Antigen, CD 120a .
Antigen, CD120a .
Receptor, TNFRSF1A .
Antigens, CD120a .
CD120a Antigens .
Receptors, Tumor Necrosis Factor, Member 1A .
Tumor Necrosis Factor Receptor Superfamily, Member 1A .
Tumor Necrosis Factor Receptor Type I .
A tumor necrosis factor receptor subtype that has specificity for TUMOR NECROSIS FACTOR ALPHA and LYMPHOTOXIN ALPHA. It is constitutively expressed in most tissues and is a key mediator of tumor necrosis factor signaling in the vast majority of cells. The activated receptor signals via a conserved death domain that associates with specific TNF RECEPTOR-ASSOCIATED FACTORS in the CYTOPLASM. .
0.32
143882